Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Piperacillin-Tazobactam vs AMCILL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Community-acquired pneumonia,Nosocomial pneumonia,Septicemia,Febrile neutropenia (off-label),Bone and joint infections (off-label)
Infections of the respiratory tract,Infections of the genitourinary tract,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Prophylaxis of bacterial endocarditis
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
Piperacillin undergoes minor hepatic metabolism; tazobactam is metabolized to a minor inactive metabolite. Both are primarily excreted unchanged in urine via glomerular filtration and tubular secretion.
Partially metabolized by hydrolysis; primarily excreted unchanged in urine via renal tubular secretion and glomerular filtration.
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Piperacillin: ~30% bound to albumin; Tazobactam: ~30% bound to albumin.
20% bound, primarily to albumin.
Piperacillin: ~0.18-0.3 L/kg; Tazobactam: ~0.2-0.3 L/kg. Distributes widely into tissues, including lung, kidney, bile, peritoneal fluid, and inflamed tissues.
0.3 L/kg; indicates distribution into extracellular fluid.
IV only; oral bioavailability negligible (not orally administered).
Oral: 50-70% (variable, reduced by food); IM: nearly 100%.
Cr Cl 20-40 m L/min: 2.25 g IV every 6 hours; Cr Cl <20 m L/min: 2.25 g IV every 8 hours; hemodialysis: 2.25 g IV every 12 hours, plus 0.75 g after dialysis.
For Cr Cl 30-50 m L/min: administer every 12 hours; for Cr Cl 10-29 m L/min: administer every 18-24 hours; for Cr Cl <10 m L/min: administer every 24 hours.
No dosage adjustment required for hepatic impairment. Use caution in patients with hepatic encephalopathy or severe hepatic dysfunction.
No specific adjustments recommended for Child-Pugh A or B; use caution in severe hepatic impairment (Child-Pugh C) with monitoring.
Infants and children: 100 mg piperacillin/kg/dose IV every 6-8 hours (max 4 g piperacillin per dose); for pseudomonal infections, up to 200 mg/kg/dose IV every 6 hours.
Children >1 month: 25-50 mg/kg/day orally divided every 8 hours; for severe infections, up to 100 mg/kg/day IV divided every 6 hours. Maximum dose: 2 g/day.
Start at the lower end of dosing; adjust primarily based on renal function. Monitor renal function closely and modify dose according to creatinine clearance.
No specific dose adjustment required; monitor renal function and adjust based on creatinine clearance.
No FDA black box warnings.
No FDA black box warning.
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Hematologic toxicity (neutropenia, thrombocytopenia) with prolonged therapy,Renal impairment requiring dose adjustment,Electrolyte disturbances (hypokalemia),Neuromuscular irritability or seizures with high doses or renal failure
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Superinfection,Risk of seizures with high doses or renal impairment,Use caution in patients with mononucleosis (high risk of rash)
Known hypersensitivity to piperacillin, tazobactam, or any beta-lactam antibiotic,History of anaphylactic reaction to penicillins, cephalosporins, or carbapenems
Hypersensitivity to ampicillin, penicillins, or any component of the formulation,Infections caused by beta-lactamase-producing organisms
No significant food interactions; take with or without food. Avoid alcohol during therapy.
Food does not significantly affect absorption; may be taken with or without meals. Avoid alcohol: may increase risk of disulfiram-like reaction (rare).
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is generally acceptable for serious infections.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearly needed; potential for altered gut flora and diarrhea in neonate.
Piperacillin and tazobactam are excreted into human milk in low concentrations. M/P ratio for piperacillin is approximately 0.11. No adverse effects on nursing infants are anticipated. Use with caution, especially if breastfeeding a premature infant or one with renal impairment.
Ampicillin is excreted in breast milk in low concentrations (M/P ratio approximately 0.2). Compatible with breastfeeding; monitor infant for diarrhea or rash.
No dose adjustment is routinely required for pregnancy alone. However, pregnancy-related increases in renal clearance may necessitate higher doses or more frequent administration for severe infections. Monitor clinical response and consider therapeutic drug monitoring.
Increased renal clearance during pregnancy may require higher doses to maintain therapeutic levels. Standard dosing is usually adequate for most indications; consider monitoring serum levels in severe infections.
Piperacillin-tazobactam (Zosyn) exhibits time-dependent killing; optimal efficacy requires frequent dosing (every 6 hours) with extended infusion (4 hours) for critically ill patients. Adjust dose for renal impairment; Cr Cl <20 m L/min: max 2.25 g every 8 hours. Monitor for bleeding risk due to platelet dysfunction at high doses. Contains sodium (2.79 m Eq per gram of piperacillin); caution in heart failure. Do not co-administer with aminoglycosides in same IV line; use separate sites.
AMCILL (ampicillin) is a broad-spectrum penicillinase-sensitive penicillin. Use caution in patients with renal impairment; dose adjustment required for Cr Cl <30 m L/min. Monitor for hypersensitivity reactions, especially in patients with cephalosporin allergy. IV administration may cause phlebitis; rotate infusion sites. Not effective against penicillinase-producing organisms including Staphylococcus aureus.
Take this medication exactly as prescribed; do not skip doses even if feeling better.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.,This drug may cause diarrhea, nausea, or headache; contact your doctor if severe or persistent.,Inform your doctor if you have kidney disease, heart failure, or bleeding disorders.,Avoid alcohol while taking this medication to reduce risk of adverse effects.
Take exactly as prescribed; complete full course even if you feel better.,Notify your doctor if you develop rash, hives, or difficulty breathing.,May cause diarrhea; contact your doctor if severe or bloody.,Take with a full glass of water; avoid acidic beverages like orange juice.,Inform your doctor if you are pregnant, breastfeeding, or taking oral contraceptives (ampicillin may reduce efficacy).
"Tazobactam, a beta-lactamase inhibitor, may reduce the therapeutic efficacy of picosulfuric acid, a stimulant laxative, by altering gut microbiota composition and reducing bacterial enzymatic conversion of the prodrug to its active metabolite. This can lead to diminished laxative effect and inadequate bowel preparation for colonoscopy. Patients may experience suboptimal colonic cleansing, potentially compromising diagnostic accuracy."
"Tazobactam, a beta-lactamase inhibitor, may reduce the serum concentration of doxorubicin, an anthracycline antineoplastic agent, potentially decreasing its cytotoxic efficacy. This interaction is hypothesized to occur through tazobactam's induction of drug transporters such as P-glycoprotein, enhancing doxorubicin efflux and lowering intracellular accumulation. Reduced doxorubicin exposure could compromise therapeutic outcomes in cancer patients, increasing the risk of treatment failure."
"Tazobactam, a beta-lactamase inhibitor, can reduce the serum concentration of Netilmicin, an aminoglycoside antibiotic, potentially diminishing its bactericidal efficacy. This interaction likely occurs through physicochemical inactivation in vivo, where beta-lactam compounds form a covalent bond with the aminoglycoside's amino groups, reducing its antimicrobial activity. Clinically, this may lead to subtherapeutic aminoglycoside levels, treatment failure, or increased risk of infection progression, particularly in immunocompromised patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Piperacillin-Tazobactam vs AMCILL, answered by our medical review team.
Piperacillin-Tazobactam is a Penicillin Antibiotic + Beta-Lactamase Inhibitor that works by Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.. AMCILL is a Penicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Piperacillin-Tazobactam and AMCILL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Piperacillin-Tazobactam is: 3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.. The standard adult dose of AMCILL is: 250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Piperacillin-Tazobactam and AMCILL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Piperacillin-Tazobactam is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is . AMCILL is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: Not associated with major birth defects. Second and third trimesters: Use only if clearl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.